Human Metabolome Technologies (TSE:6090) ROCE % : 39.20% (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Human Metabolome Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Human Metabolome Technologies's annualized ROCE % for the quarter that ended in Mar. 2024 was 39.20%.

Human Metabolome Technologies ROCE % Historical Data

The historical data trend for Human Metabolome Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Human Metabolome Technologies ROCE % Chart

Human Metabolome Technologies Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Jun20

Jun21

Jun22

ROCE %

Get a 7-Day Free Trial

-8.09

-21.70

-1.78

4.13

18.68

Human Metabolome Technologies Quarterly Data
	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															43.09	-7.12	-2.78	23.55	39.20

Human Metabolome Technologies ROCE % Calculation

Human Metabolome Technologies's annualized ROCE % for the fiscal year that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2022 )		(A: Jun. 2021 )		(A: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2022 )		(A: Jun. 2021 )		(A: Jun. 2022 )
	=	264.125	/	( ( (1623.17 - 317.327)	+	(2068.728 - 546.279) )	/ 2 )
	=	264.125	/	( (1305.843	+	1522.449)	/ 2 )
	=	264.125	/	1414.146
	=	18.68 %

Human Metabolome Technologies's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	735.04	/	( ( (2201.659 - 411.337)	+	(2494.315 - 534.579) )	/ 2 )
	=	735.04	/	( ( 1790.322	+	1959.736 )	/ 2 )
	=	735.04	/	1875.029
	=	39.20 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Human Metabolome Technologies (TSE:6090) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Human Metabolome Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Human Metabolome Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Human Metabolome Technologies (TSE:6090) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Human Metabolome Technologies Inc (TSE:6090) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yamagata Prefecture Kakuganji Water 246-2, Tsuruoka, JPN, 997-0052

Website

http://www.humanmetabolome.com

Human Metabolome Technologies, Inc is involved in the search and diagnosis of biomarkers and commercialization in the field of drug development.

Human Metabolome Technologies (TSE:6090) Headlines

No Headlines